Olanzapin Kullanımına Bağlı Derin Ven Trombozu

Abstract

Atipik antipsikotik ilaçlar ekstrapramidal yan etki oluşturma riskleri düşük olduğu için başta şizofreni ve manide giderek artan oranlarda kullanılmaktadır. Atipik antipsikotik ilaç kullanımında başta obezite ve dislipidemi gibi birçok metabolik yan etki oluşabilmektedir. Atipik antipsikotik ilaç kullanımı ve venöz tromboemboli gelişimi arasında ilişki olabileceğini gösteren çalışmaların sayısı giderek artmaktadır. Acil servisimize bacakta ağrı ve şişlik sebebiyle başvuran ve bipolar bozukluk nedeniyle olanzapin kulllanan 33 yaşında erkek hastada derin ven trombozu saptadık. Biz bu olgu sunumunda venöz tromboemboli gelişimi için risk faktörlerinin olmadığı hastada olanzapine kullanımının derin ven trombozuna yol açabileceğini tartıştık.

Keywords

• Olanzapin, derin ven trombozu

Olanzapine Induced Deep Venous Thrombosis

Abstract

Cause of a lower risk of extrapyramidal side effects atypical antipsychotic drugs are primarily being used more frequently in schizophrenia and mania. Many metabolic side effects particularly such as obesity and dyslipidemia may occur in the use of atypical antipsychotic drugs. Numbers of studies that show a relationship between atypical antipsychotic use and the development of venous thromboembolism have been increasing. We discovered deep venous thrombosis in 33year- old male patient, who had been using olanzapine due to bipolar disorder, admitted to our emergency service with leg pain and swelling. In this case report we discussed that in a patient without risk factors for developing venous thromboembolism, the use of olanzapine may lead to deep venous thrombosis

Keywords

• Olanzapine, deep venous thrombosis

References

1. Tomassen R, Vandenbroucke JP, Rosendal FR. Antipsychotic Medication and Venous Thrombosis. British Journal of Psychiatry. 2001;179:63-66.
2. Jonsson A, Horvath-Puho E, Hagg S, Pedersen L, Sorensen HT. Antipsychotics and Risk of Venous Thromboembolism: A population- Based Case- Control Study. Clinical Epidemiology 2009;1:19-26.
3. Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: Clinical Outcomes in the International Cooperative Pulmonary Em- bolism Registry (ICOPER). Lancet 1999;353 (9162):1386-1389.
4. Anderson FA Jr, Spencer FA. Risk Factors for Venous Thrombo- embolism. Circulation. 2003;107: 9-16.
5. Van Neste E, Verbruggen W, Leysen M. Deep Venous Thrombosis and Pulmonary Embolism in Psychiatric Settings. European Jour- nal of Psychiatry. 2009;23(1):19-30.
6. Yeh J, Lee A. Clozapine-Induced Pulmonary Embolism: A Case Re- port and Literature Review. Hospital Pharmacy. 2009;44(1):36-40.
7. Hagg S, Bate A, Stahl M, Spigset O. Associations Between Ve- nous Thromboembolism and Antipsychotics. Drug Safety. 2008;31(8):685-694.
8. Maempel JFZ, Darmanin G, Naeem K, Patel M. Olanzapine and Pulmonary Embolism, A Rare Association: A Case Report. Cases Journal 2010;3:36.

9. Kannan R, Molina DK. Olanzapine: A New Risk Factor for Pul- monary Embolus?. American Journal of Forensic Medicine and Pathology. 2008;29(4):368-370.
10. Liperoti R, Pedone C, Lapane KL, Mor V. Venous Thromboem- bolism Among Elderly Patients Treated with Atypical and Con- ventional Antipsychotic Agents. Archives of Internal Medicine. 2005;165:2677-2682.